News Extra [these Stories Appear Only On The Web]

Trastuzumab halves risk of recurrence of breast cancer in some women

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.986-d (Published 27 October 2005) Cite this as: BMJ 2005;331:986
  1. Roger Dobson
  1. Abergavenny

    The result of three trials of trastuzumab (Herceptin) seem to show that the drug, used as adjuvant therapy after surgical treatment of primary breast cancer, halves the recurrence rate of breast cancer in certain women and reduces mortality by 33%.

    Two papers published last week summarise the results of three trials—the combined results of the National Surgical Adjuvant Breast and Bowel Project trial plus the North …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe